Showing results (81-90 of 180) with videos related to
Sort By:
Pageof 18
The Lancet. Haematology|February 11, 2019
A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation studyGordon Cook, Kara-Louise Royle, Charlotte Pawlyn, et al.Haematologica|August 24, 2019
Chimeric antigen receptor T-cell therapy for multiple myeloma: a consensus statement from The European Myeloma NetworkPhilippe Moreau, Pieter Sonneveld, Mario Boccadoro, et al.Blood|December 23, 2022
Optimizing the value of lenalidomide maintenance by extended genetic profiling: an analysis of 556 patients in the Myeloma XI trialAikaterini Panopoulou, David A Cairns, Amy Holroyd, et al.Frontiers in Oncology|August 9, 2021
Defining Unmet Need Following Lenalidomide Refractoriness: Real-World Evidence of Outcomes in Patients With Multiple MyelomaCatherine S Y Lecat, Jessica B Taube, William Wilson, et al.Blood Advances|October 26, 2021
Primary graft failure, but not relapse, may be identified by early chimerism following double cord blood unit transplantationRachael Hough, Andre Lopes, Pip Patrick, et al.Blood|August 27, 2013
The impact of response on bone-directed therapy in patients with multiple myelomaAlessandra Larocca, J Anthony Child, Gordon Cook, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|October 19, 2011
High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation RegistryNicolas Mounier, Carmen Canals, Christian Gisselbrecht, et al.Blood Cancer Journal|February 19, 2021
Management of patients with multiple myeloma beyond the clinical-trial setting: understanding the balance between efficacy, safety and tolerability, and quality of lifeEvangelos Terpos, Joseph Mikhael, Roman Hajek, et al.Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners|September 6, 2022
Switching to daratumumab SC from IV is safe and preferred by patients with multiple myelomaMaria-Victoria Mateos, Sophie Rigaudeau, Supratik Basu, et al.Clinical Hematology International|October 1, 2021
How to Simplify the Evaluation of Newly Introduced Chemotherapeutic Interventions in MyelomaTreen Carson Michael Morris, Mary B Drake, Paul J Kettle, et al.Pageof 18